Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Connect® MM- The Multiple Myeloma Disease Registry

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: March 4, 2010
Last updated: July 8, 2016
Last verified: July 2016
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Multiple Myeloma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Connect® MM- The Multiple Myeloma Disease Registry

Resource links provided by NLM:

Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Identify and summarize patterns in therapeutic regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies in patients newly diagnosed with symptomatic MM in the community and academic setting

  • Identify and summarize patterns in therapeutic regimens and patient outcomes [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with symptomatic MM

Secondary Outcome Measures:
  • Summarize Effectiveness of Treatment Regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM

  • Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes

Enrollment: 3011
Study Start Date: September 2009
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)
Group One: Patients enrolled between Sep2009 and Nov2011
Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
Group Two: Patients enrolled between Dec2012 and mid-2016
Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with multiple myoloma and being treated in community or academic settings.

Inclusion Criteria:

  • Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect®MM registry
  • Age ≥18 years
  • Willing and able to provide signed informed consent
  • Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Exclusion Criteria:

- None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01081028

  Show 253 Study Locations
Sponsors and Collaborators
Celgene Corporation
Study Director: Mohamad Hussein, MD Celgene Corporation
  More Information

Responsible Party: Celgene Corporation Identifier: NCT01081028     History of Changes
Other Study ID Numbers: Connect ® MM 
Study First Received: March 4, 2010
Last Updated: July 8, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Celgene Corporation:
Multiple Myeloma
disease registry

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases processed this record on October 28, 2016